The Institute of Cancer Research - Professor Kevin Harrington (ICR + Royal Marsden NHS Foundation Trust) responds to today's news of the 2018 Nobel Prize for Physiology or Medicine being awarded to
![The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined](https://pbs.twimg.com/media/FUeZSb3WYAEpqX9.png)
The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined
![ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/images/default-source/default-album/june-dc---kevin-43.jpg?sfvrsn=949d3069_0)
ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London
![The ICR on Twitter: "Professor Kevin Harrington specialises in #HeadAndNeckCancer. He and his team study the use of biologically targeted agents, in combination with treatments such as #Radiotherapy and #Chemotherapy, to target # The ICR on Twitter: "Professor Kevin Harrington specialises in #HeadAndNeckCancer. He and his team study the use of biologically targeted agents, in combination with treatments such as #Radiotherapy and #Chemotherapy, to target #](https://pbs.twimg.com/media/FYrs27nXoAEamGb.png)
The ICR on Twitter: "Professor Kevin Harrington specialises in #HeadAndNeckCancer. He and his team study the use of biologically targeted agents, in combination with treatments such as #Radiotherapy and #Chemotherapy, to target #
![Radiotherapy supercharges cancer-targeting viruses to treat deadly skin cancer - The Institute of Cancer Research, London Radiotherapy supercharges cancer-targeting viruses to treat deadly skin cancer - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/default-album/t-vec-infected-melanoma-cells-(green)_kevin-harrington-embed.jpg?sfvrsn=70547b69_2)
Radiotherapy supercharges cancer-targeting viruses to treat deadly skin cancer - The Institute of Cancer Research, London
![The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies](https://pbs.twimg.com/media/EksuaANXIAAxAzY.jpg)
The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies
![High-tech radiotherapy, drug combinations and immunotherapy showcased as future of cancer treatment - The Institute of Cancer Research, London High-tech radiotherapy, drug combinations and immunotherapy showcased as future of cancer treatment - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/default-album/the-icr's-professor-kevin-harrington-at-the-cheltenham-science-festival.jpg?sfvrsn=57f36269_0)
High-tech radiotherapy, drug combinations and immunotherapy showcased as future of cancer treatment - The Institute of Cancer Research, London
The ICR on Twitter: "Professors Kevin Harrington and Alan Melcher (ICR + @royalmarsdenNHS) featured earlier in a @BBCr4today segment on #immunotherapy. In the UK you can still listen to today's live program
![The ICR on Twitter: "Watch Professor Kevin Harrington on @BBCLondonNews as he shares more on how a modified version of the herpes virus could offer hope for some people with advanced #Cancer. The ICR on Twitter: "Watch Professor Kevin Harrington on @BBCLondonNews as he shares more on how a modified version of the herpes virus could offer hope for some people with advanced #Cancer.](https://pbs.twimg.com/media/Fd0_KuNaEAEhWJ5.png)
The ICR on Twitter: "Watch Professor Kevin Harrington on @BBCLondonNews as he shares more on how a modified version of the herpes virus could offer hope for some people with advanced #Cancer.
![ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/images/default-source/default-album/icr-rmh-clarivate-highly-cited-researchers-2021-2-945x532.tmb-0945x532.jpg?sfvrsn=3d922b69_1)
ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London
![Connections blog - ICR celebrates innovation and commercialisation at staff awards - The Institute of Cancer Research, London Connections blog - ICR celebrates innovation and commercialisation at staff awards - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/images/default-source/default-album/jon-wilkinson-547x410.jpg?sfvrsn=c5d13369_0)
Connections blog - ICR celebrates innovation and commercialisation at staff awards - The Institute of Cancer Research, London
![The ICR on Twitter: "ICR's Professor Kevin Harrington speaks about the @NICEcomms news about immunotherapy #nivolumab https://t.co/pRd7KUmAmR #CancerDrugsFund https://t.co/ompikxJVHr" / Twitter The ICR on Twitter: "ICR's Professor Kevin Harrington speaks about the @NICEcomms news about immunotherapy #nivolumab https://t.co/pRd7KUmAmR #CancerDrugsFund https://t.co/ompikxJVHr" / Twitter](https://pbs.twimg.com/media/DMFIh_3X0AAF17g.jpg)
The ICR on Twitter: "ICR's Professor Kevin Harrington speaks about the @NICEcomms news about immunotherapy #nivolumab https://t.co/pRd7KUmAmR #CancerDrugsFund https://t.co/ompikxJVHr" / Twitter
![Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma | The Royal Marsden Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma | The Royal Marsden](https://rm-d8-live.s3.eu-west-1.amazonaws.com/d8live.royalmarsden.nhs.uk/s3fs-public/styles/hero_standard/public/Prof%20Kev%20Har.jpg?itok=mnjHeltm)
Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma | The Royal Marsden
![Tumour assassination – using smart targeted treatments to enhance anti-cancer radiation responses - The Institute of Cancer Research, London Tumour assassination – using smart targeted treatments to enhance anti-cancer radiation responses - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/researchers/professor-kevin-harrington-(jon-enoch-for-the-icr-2012).jpg?sfvrsn=a729a68_4)
Tumour assassination – using smart targeted treatments to enhance anti-cancer radiation responses - The Institute of Cancer Research, London
![Scientists reveal new lines of attack to raise cancer survival rate | Cancer research | The Guardian Scientists reveal new lines of attack to raise cancer survival rate | Cancer research | The Guardian](https://i.guim.co.uk/img/media/218aadacfc2a08dd4c0ddf1515a93c1165171199/0_0_5076_3047/master/5076.jpg?width=1200&quality=85&auto=format&fit=max&s=fc5e1ce6efd4e88f190d783030a54b65)